Skip to main content

Common Fund ARRA Research

ARRA LogoRecovery Act funding awarded by the NIH Common Fund is supporting cutting-edge biomedical research in a variety of diverse areas and is helping expand the technologies and capabilities available to scientists and clinicians, deepen our understanding of fundamental biological processes in health and disease, and develop new approaches to the prevention, diagnosis, and treatment of many common diseases and disorders. ARRA funds awarded by the Common Fund are also preserving and creating jobs across the United States.

The following are some of the many critical areas of research being supported by ARRA funds awarded through the NIH Common Fund:

Behavioral & Social ScienceBehavioral & Social Science
Behavior and Social Science: modest changes in personal behavior have been shown to improve health dramatically.
 

CancerCancer
Cancer arises when genetic mutations produce cells that no longer obey the rules governing cellular behavior.
 

EpigeneticsEpigenetics
Epigenetics refers to processes that control the activities of genes but do not involve changes such as mutations to the DNA sequence of the genome.
 

High Throughput TechnologiesHigh Throughput Technologies
High Throughput Technologies allow researchers to rapidly analyze large numbers of substances and chemical compounds.
 

Human MicrobiomeHuman Microbiome
The Human Microbiome refers to the communities of microbial cells that reside on and in our bodies and that may critical influence human health and disease.
 

Regenerative MedicineRegenerative Medicine
Regenerative Medicine aims to engage and facilitate the body’s healing capabilities to repair damaged tissues and organs.
 

S.T.E.M. EducationS.T.E.M. Education
S.T.E.M. (science, technology, engineering, and math) Education across the U.S. is being  supported by Common Fund ARRA awards.
 

Stem CellsStem Cells
Stem Cells are renewable sources of transplantable cells that may be used to treat a variety of diseases and disorders.

This page last reviewed on July 17, 2023